Global law firm Clifford Chance has advised dsm-firmenich, innovators in nutrition, health, and beauty, on the sale of its stake in the Feed Enzymes Alliance to its equal partner Novonesis, a global leader in biosolutions, for €1.5 billion.
The dsm-firmenich activities to be sold under this transaction to Novonesis represented in 2024 approximately €300 million in total annual net sales. Novonesis will continue a long-term commercial relationship with the Animal Nutrition & Health business, for the re-sale of its feed enzymes through the Animal Nutrition & Health world-class premix network.
At dsm-firmenich, the feed enzymes business is currently part of the Animal Nutrition & Health business unit, which itself will be separated from the Group to operate under new ownership, as announced in February 2024.
This transaction is expected to be completed in the course of 2025, subject to customary conditions and regulatory approvals.
The cross-border Clifford Chance team was led by Gregory Crookes, Stephanie Horowitz, Pieter Leefers, Sabine van den Heuvel and Chris in ‘t Veld, and further consisted of Marc Besen, Jurre Jurriens and Fiorri Michael (Antitrust), Gunnar Sachs and Kathrin Schroeder-Finckh (Corporate Regulatory – Healthcare, Life Science & Chemicals), Claudia Milbradt and Nicolas Hohn-Hein (Intellectual Property), Floris van de Bult, Florence Aubonnet, Merle van den Berg, Alexander Stemmler and Iga Mamczarz (Employment), Wijnanda Rutten (Pensions), Michiel Sunderman and Alec Sanderson (Tax), Orsolya Gondos and Tamlin Higgins (Tech//Digital), and Robert Bulte (Corporate).
